Related Experiment Video
Updated: Jun 27, 2025
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
378
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort-a Retrospective Review
Joseph Joseph1,2, Kelvin Truong1,2, Serigne N Lo1,3
1Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Dermatology and Therapy
|April 25, 2024
Summary
Biologic therapy significantly improved psoriasis skin severity but did not alter cardiovascular disease risk factors like blood pressure or BMI after one year in patients with psoriasis.
Area of Science:
- Dermatology and Cardiovascular Medicine
- Immunodermatology
- Clinical Research
Background:
- Psoriasis is a known risk factor for cardiovascular disease (CVD).
- Biologic agents represent a breakthrough in managing psoriatic skin lesions.
- This study investigates the impact of continuous biologic treatment on CVD risk factors in psoriasis patients.
Purpose of the Study:
- To evaluate changes in cardiovascular risk factors after one year of continuous biologic therapy in patients with chronic plaque psoriasis.
- To assess the relationship between skin improvement and cardiovascular risk markers.
Main Methods:
- Retrospective review of 106 patients with chronic plaque psoriasis treated with biologics.
- Psoriasis Area and Severity Index (PASI) used to measure skin improvement.
- Cardiovascular risk factors assessed included body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR).
- Paired t-tests compared baseline and 1-year follow-up measurements.
Main Results:
- Significant improvement in psoriasis severity (PASI reduction from 17.4 to 1.4, p < 0.001).
- No statistically significant changes were observed in SBP, DBP, BMI, or HR after 1 year of treatment.
- Mean BMI at baseline was 30 kg/m², with no significant change observed.
Conclusions:
- One year of continuous biologic therapy leads to substantial skin improvement in psoriasis patients.
- Despite significant dermatological benefits, biologic therapy did not demonstrate improvement in key cardiovascular disease risk factors within the study period.
- Further research is needed to explore long-term cardiovascular outcomes and potential interventions in this patient population.
Keywords:
Biologic therapyCardiovascular diseaseCardiovascular risk factorsPsoriasisRetrospective reviewMore Related Videos
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
3.9K
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.3K
Related Concept Videos
01:27Psychoneuroimmunology: Cardiovascular Disease
30
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
30
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
169
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K